Skip to contentX
Xenon Pharmaceuticals Inc.
X
XENEXenon Pharmaceuticals Inc. Q3 2019 · 10-Q
Revenue$3.50M$3.50Mno prior Q3 2018 on file Net Income-$8.87M-$8.87MN/M vs Q3 2018 EPS Diluted-$0.33-$0.33N/M vs Q3 2018 Operating Income-$8,951,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Xenon Pharmaceuticals Inc. · CIK 1582313 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$7,103,000N/M Margins · derivedOperating margin-255.7%
Net margin-253.5%
ended Sep 30, 2019 · filed Nov 5, 2019 · 36 d after period end